Richard Haynes

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380

• Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials

  Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology

• The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs

  Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes

• Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).

  Aung T. et al, (2016), Trials, 17

• The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.

  Quach K. et al, (2016), American Journal of Kidney Diseases, 68, 591 - 598

• Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

  Mihaylova B. et al, (2016), American Journal of Kidney Diseases

• Niacin: old habits die hard.

  Haynes R. and Rahimi K., (2016), Heart, 102, 170 - 171

• Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.

  Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39

• Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, SEARCH and HPS2-THRIVE studies

  Parish S. et al, (2015), EUROPEAN HEART JOURNAL, 36, 981 - 981

• Neprilysin inhibition in chronic kidney disease.

  Judge P. et al, (2015), Nephrol Dial Transplant, 30, 738 - 743

• IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE

  Morton RL. et al, (2015), NEPHROLOGY DIALYSIS TRANSPLANTATION, 30

• Chronic kidney disease: Statins in chronic kidney disease: time to move on?

  Haynes R. and Wanner C., (2015), Nat Rev Nephrol, 11, 262 - 263

• What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

  Kent S. et al, (2015), BMC Nephrol, 16

• Alemtuzumab induction therapy in kidney transplantation - Authors' reply.

  Haynes R. et al, (2015), Lancet, 385

• Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.

  Herrington W. et al, (2015), Clin Chim Acta, 439, 112 - 114

• Evidence for the Prevention and Treatment of Stroke in Dialysis Patients

  Herrington W. et al, (2015), Seminars in Dialysis, 28, 35 - 47

• Evidence for the prevention and treatment of stroke in dialysis patients.

  Herrington W. et al, (2015), Semin Dial, 28, 35 - 47

• Adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events

  Landray MJ. et al, (2014), ANNALS OF INTERNAL MEDICINE, 161, JC8 - JC8

• Niacin for reduction of cardiovascular risk.

  Landray MJ. et al, (2014), N Engl J Med, 371, 1943 - 1944

• Pooled RCTs: atorvastatin did not increase renal-related serious adverse events.

  Herrington W. and Haynes R., (2014), Ann Intern Med, 161

• Effects of lowering LDL cholesterol on progression of kidney disease.

  Haynes R. et al, (2014), J Am Soc Nephrol, 25, 1825 - 1833

• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial

  Haynes R. et al, (2014), The Lancet

• Effects of extended-release niacin with laropiprant in high-risk patients.

  HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212

• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation

  Haynes R. et al, (2014), TRANSPLANTATION, 98, 155 - 155

• Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).

  Haynes R. et al, (2014), Am J Kidney Dis, 64, 40 - 48

• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation

  Haynes R. et al, (2014), AMERICAN JOURNAL OF TRANSPLANTATION, 14, 155 - 155

• The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.

  Herrington W. et al, (2014), Clin J Am Soc Nephrol, 9, 914 - 919

• Quiz page September 2013: a crystal clear diagnosis.

  MacEwen C. et al, (2013), Am J Kidney Dis, 62, xxvi - xxix

• Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?

  Haynes R. and Wheeler DC., (2013), Nat Rev Nephrol, 9, 438 - 439

• Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

  Haynes R. et al, (2013), Transplant Res, 2

• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

  HPS2-THRIVE Collaborative Group None., (2013), Eur Heart J, 34, 1279 - 1291

• Does prophylactic anticoagulation reduce the risk of femoral tunneled dialysis catheter-related complications.

  Herrington WG. et al, (2013), J Vasc Access, 14, 135 - 142

• Myeloma kidney: improving clinical outcomes?

  Haynes R. et al, (2012), Adv Chronic Kidney Dis, 19, 342 - 351

• Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE

  Hopewell JC. et al, (2012), EUROPEAN HEART JOURNAL, 33, 445 - 445

• Homocysteine, the kidney, and vascular disease.

  Haynes R. and Clarke R., (2012), BMJ, 344

• Homocysteine, the kidney, and vascular disease Moderate differences in homocysteine concentrations do not cause vascular disease

  Haynes R. and Clarke R., (2012), BRITISH MEDICAL JOURNAL, 344

• Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study.

  Haynes R. et al, (2012), Nephron Clin Pract, 120, c42 - c47

• Recruiting patients cost-effectively by mail.

  Aung T. et al, (2011), Trials, 12 Suppl 1

• Investigating strategies to improve attendance at screening visits in a randomized trial.

  Chen F. et al, (2011), Trials, 12 Suppl 1

• Serum free light chains and the risk of ESRD and death in CKD.

  Haynes R. et al, (2011), Clin J Am Soc Nephrol, 6, 2829 - 2837

• Cardiovascular aspects of chronic kidney disease

  Wheeler DC. et al, (2011), Brenner and Rector's the Kidney

• Late presentation of patients with end-stage renal disease for renal replacement therapy--is it always avoidable?

  Udayaraj UP. et al, (2011), Nephrol Dial Transplant, 26, 3646 - 3651

• Alemtuzumab: right drug, right dose?

  Haynes R. and Friend P., (2011), Transpl Int, 24, 1051 - 1052

• Simultaneous necrotizing glomerulonephritis and Hodgkin's lymphoma: a case report and review of the literature.

  Barbour TD. et al, (2011), Nephrol Dial Transplant, 26, 3403 - 3408

• Clinical trials of lipid-modifying agents: Design considerations

  Bowman L. et al, (2011), Clinical Lipidology, 6, 109 - 116

• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), Lancet, 376, 1658 - 1669

• Screening for risk with albuminuria: should we start from here?

  Haynes R. and Winearls C., (2010), Nephrol Dial Transplant, 25, 3463 - 3465

• Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.

  Emberson JR. et al, (2010), J Intern Med, 268, 145 - 154

• Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494

• Lipids in chronic kidney disease.

  Lewis D. et al, (2010), J Ren Care, 36 Suppl 1, 27 - 33

• How the NHS research governance procedures could be modified to greatly strengthen clinical research.

  Haynes R. et al, (2010), Clin Med (Lond), 10, 127 - 129

• Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.

  Haynes RJ. et al, (2010), Nephrol Dial Transplant, 25, 419 - 426

• CKD staging--evolution not revolution.

  Winearls CG. et al, (2010), Nefrologia, 30, 493 - 500

• Dual blockade of the renin-angiotensin system: are two better than one?

  Haynes R. et al, (2009), Nephrol Dial Transplant, 24, 3602 - 3607

• Aspirin for primary prevention of vascular disease in people with diabetes.

  Haynes R. et al, (2009), BMJ, 339

• Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes.

  Haynes R. et al, (2009), Nat Clin Pract Nephrol, 5, 126 - 127

• Commentary: Controversies in NICE guidance on chronic kidney disease

  Landray MJ. and Haynes RJ., (2008), BMJ, 337, 815 - 816

• Commentary: Controversies in NICE guidance on chronic kidney disease.

  Landray MJ. and Haynes RJ., (2008), BMJ, 337

• Campath-1H

  Haynes R. and Friend P., (2008), New uses of biological agents in organ transplantation

• Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency.

  Haynes R. and Armitage J., (2007), Nat Clin Pract Nephrol, 3, 530 - 531

• Proteinuria.

  Haynes J. and Haynes R., (2006), BMJ, 332

• Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)

  Staplin ND. et al, Clinical Journal of the American Society of Nephrology

• Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data.

  Haynes R. and Judge P., Nephrology, Dialysis and Transplantation

• Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

  Herrington W. et al, Hypertension

• Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the Study of Heart and Renal Protection

  Reith CA. et al, BMC Nephrology

• Biliary tract and liver complications in polycystic kidney disease

  Judge P. et al, Journal of the American Society of Nephrology

• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease

  Schlackow I. et al, Heart

Recent Publications

• Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

  Mafham MM. et al, (2017), Nephrol Dial Transplant

• Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

  Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380

• Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials

  Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology

• The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs

  Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes

• Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).

  Aung T. et al, (2016), Trials, 17